Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
P05187

UPID:
PPB1_HUMAN

ALTERNATIVE NAMES:
Alkaline phosphatase Regan isozyme; Placental alkaline phosphatase 1

ALTERNATIVE UPACC:
P05187; P05188; P06861; Q53S78; Q96DB7

BACKGROUND:
The protein Alkaline phosphatase, placental type, with alternative names such as Alkaline phosphatase Regan isozyme and Placental alkaline phosphatase 1, is identified by the accession number P05187. It is known for its ability to hydrolyze phosphate compounds, a function essential for maintaining various physiological processes.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Alkaline phosphatase, placental type offers a promising pathway to uncovering new therapeutic approaches. Its critical role in biochemical pathways underscores its potential as a target for innovative treatment modalities.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.